Cargando…

Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo

The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date, the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kluss, Jillian H., Mazza, Melissa Conti, Li, Yan, Manzoni, Claudia, Lewis, Patrick A., Cookson, Mark R., Mamais, Adamantios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977595/
https://www.ncbi.nlm.nih.gov/pubmed/33741046
http://dx.doi.org/10.1186/s13024-021-00441-8
_version_ 1783667135171526656
author Kluss, Jillian H.
Mazza, Melissa Conti
Li, Yan
Manzoni, Claudia
Lewis, Patrick A.
Cookson, Mark R.
Mamais, Adamantios
author_facet Kluss, Jillian H.
Mazza, Melissa Conti
Li, Yan
Manzoni, Claudia
Lewis, Patrick A.
Cookson, Mark R.
Mamais, Adamantios
author_sort Kluss, Jillian H.
collection PubMed
description The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date, the molecular effects of chronic LRRK2 inhibition have not yet been examined in vivo. We evaluated the utility of newly available phospho-antibodies for Rab substrates and LRRK2 autophosphorylation to examine the pharmacodynamic response to treatment with the potent and specific LRRK2 inhibitor, MLi-2, in brain and peripheral tissue in G2019S LRRK2 knock-in mice. We report higher sensitivity of LRRK2 autophosphorylation to MLi-2 treatment and slower recovery in washout conditions compared to Rab GTPases phosphorylation, and we identify pS106 Rab12 as a robust readout of downstream LRRK2 activity across tissues. The downstream effects of long-term chronic LRRK2 inhibition in vivo were evaluated in G2019S LRRK2 knock-in mice by phospho- and total proteomic analyses following an in-diet administration of MLi-2 for 10 weeks. We observed significant alterations in endolysosomal and trafficking pathways in the kidney that were sensitive to MLi-2 treatment and were validated biochemically. Furthermore, a subtle but distinct biochemical signature affecting mitochondrial proteins was observed in brain tissue in the same animals that, again, was reverted by kinase inhibition. Proteomic analysis in the lung did not detect any major pathway of dysregulation that would be indicative of pulmonary impairment. This is the first study to examine the molecular underpinnings of chronic LRRK2 inhibition in a preclinical in vivo PD model and highlights cellular processes that may be influenced by therapeutic strategies aimed at restoring LRRK2 physiological activity in PD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00441-8.
format Online
Article
Text
id pubmed-7977595
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79775952021-03-22 Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo Kluss, Jillian H. Mazza, Melissa Conti Li, Yan Manzoni, Claudia Lewis, Patrick A. Cookson, Mark R. Mamais, Adamantios Mol Neurodegener Research Article The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date, the molecular effects of chronic LRRK2 inhibition have not yet been examined in vivo. We evaluated the utility of newly available phospho-antibodies for Rab substrates and LRRK2 autophosphorylation to examine the pharmacodynamic response to treatment with the potent and specific LRRK2 inhibitor, MLi-2, in brain and peripheral tissue in G2019S LRRK2 knock-in mice. We report higher sensitivity of LRRK2 autophosphorylation to MLi-2 treatment and slower recovery in washout conditions compared to Rab GTPases phosphorylation, and we identify pS106 Rab12 as a robust readout of downstream LRRK2 activity across tissues. The downstream effects of long-term chronic LRRK2 inhibition in vivo were evaluated in G2019S LRRK2 knock-in mice by phospho- and total proteomic analyses following an in-diet administration of MLi-2 for 10 weeks. We observed significant alterations in endolysosomal and trafficking pathways in the kidney that were sensitive to MLi-2 treatment and were validated biochemically. Furthermore, a subtle but distinct biochemical signature affecting mitochondrial proteins was observed in brain tissue in the same animals that, again, was reverted by kinase inhibition. Proteomic analysis in the lung did not detect any major pathway of dysregulation that would be indicative of pulmonary impairment. This is the first study to examine the molecular underpinnings of chronic LRRK2 inhibition in a preclinical in vivo PD model and highlights cellular processes that may be influenced by therapeutic strategies aimed at restoring LRRK2 physiological activity in PD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00441-8. BioMed Central 2021-03-19 /pmc/articles/PMC7977595/ /pubmed/33741046 http://dx.doi.org/10.1186/s13024-021-00441-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kluss, Jillian H.
Mazza, Melissa Conti
Li, Yan
Manzoni, Claudia
Lewis, Patrick A.
Cookson, Mark R.
Mamais, Adamantios
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title_full Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title_fullStr Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title_full_unstemmed Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title_short Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
title_sort preclinical modeling of chronic inhibition of the parkinson’s disease associated kinase lrrk2 reveals altered function of the endolysosomal system in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977595/
https://www.ncbi.nlm.nih.gov/pubmed/33741046
http://dx.doi.org/10.1186/s13024-021-00441-8
work_keys_str_mv AT klussjillianh preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT mazzamelissaconti preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT liyan preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT manzoniclaudia preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT lewispatricka preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT cooksonmarkr preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo
AT mamaisadamantios preclinicalmodelingofchronicinhibitionoftheparkinsonsdiseaseassociatedkinaselrrk2revealsalteredfunctionoftheendolysosomalsysteminvivo